The synthetic triterpenoid RTA dh404 (CDDO-dhTFEA) restores endothelial function impaired by reduced Nrf2 activity in chronic kidney disease

Redox Biology

Volumn 1, Issue 1, 2013, Pages 527-531

  Aminzadeh, Mohammad A ^a   Reisman, Scott A ^b   Vaziri, Nosratola D ^a   Shelkovnikov, Stan ^a   Farzaneh, Seyed H ^a   Khazaeli, Mahyar ^a   Meyer, Colin J ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Reata Pharmaceuticals Inc   (United States)

Author keywords

Aorta; Bardoxolone methyl; Chronic kidney disease; Inflammation; Nrf2; Oxidative stress; Synthetic triterpenoid

Indexed keywords

3 NITROTYROSINE; ACETYLCHOLINE; ANGIOTENSIN RECEPTOR; ANTIOXIDANT; ARACHIDONATE 12 LIPOXYGENASE; MONOCYTE CHEMOTACTIC PROTEIN 1; OLEANOLIC ACID; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RTADH 404; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG; DH404 COMPOUND; NFE2L2 PROTEIN, RAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CELL PROTECTION; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DRUG EFFICACY; ENDOTHELIAL DYSFUNCTION; GENE ACTIVITY; GENE EXPRESSION REGULATION; GENE TARGETING; MALE; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; RAT; UPREGULATION; VASCULAR RING; VASODILATATION; ANALOGS AND DERIVATIVES; ANIMAL; AORTA; CYTOLOGY; DRUG EFFECTS; ENDOTHELIUM CELL; INFLAMMATION; METABOLISM; OXIDATIVE STRESS; PATHOLOGY; RENAL INSUFFICIENCY, CHRONIC; SPRAGUE DAWLEY RAT;

ANIMALS; AORTA; ENDOTHELIAL CELLS; GENE EXPRESSION REGULATION; INFLAMMATION; MALE; NEPHRECTOMY; NF-E2-RELATED FACTOR 2; OLEANOLIC ACID; OXIDATIVE STRESS; RATS; RATS, SPRAGUE-DAWLEY; RENAL INSUFFICIENCY, CHRONIC;

EID: 84888070080     PISSN: 22132317     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.redox.2013.10.007     Document Type: Article

References (27)

1. Go A.S., Chertow G.M., Fan D., McCulloch C.E., Hsu C.Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N. Engl. J. Med. 2004, 351:1296-1305.
2. Napoli C., Casamassimi A., Crudele V., Infante T., Abbondanza C. Kidney and heart interactions during cardiorenal syndrome: a molecular and clinical pathogenic framework. Future Cardiol. 2011, 7:485-497.
3. Vaziri N.D., Rodriguez-Iturbe B. Mechanisms of disease: oxidative stress and inflammation in the pathogenesis of hypertension. Nat. Clin. Pract. Nephrol. 2006, 2:582-593.
4. Gokce G., Kerry Z. Oxidative stress attenuates phenylephrine-induced contractile responses in rat aorta Hacettepe University. J. Faculty Pharm. 2005, 25:61-70.
5. Talebianpoor M.S., Mirkhani H. The effect of tempol administration on the aortic contractile responses in rat preeclampsia model. ISRN Pharmacol. 2012, 2012:187208.
6. Klaassen C.D., Reisman S.A. Nrf2 the rescue: effects of the antioxidative/electrophilic response on the liver. Toxicol. Appl. Pharmacol. 2010, 244:57-65.
7. Sporn M.B., Liby K.T., Yore M.M., Fu L., Lopchuk J.M., Gribble G.W. New synthetic triterpenoids: potent agents for prevention and treatment of tissue injury caused by inflammatory and oxidative stress. J. Nat. Prod. 2011, 74:537-545.
8. Yates M.S., Tauchi M., Katsuoka F., Flanders K.C., Liby K.T., Honda T., Gribble G.W., Johnson D.A., Johnson J.A., Burton N.C., Guilarte T.R., Yamamoto M., Sporn M.B., Kensler T.W. Pharmacodynamic characterization of chemopreventive triterpenoids as exceptionally potent inducers of Nrf2-regulated genes. Mol. Cancer Ther. 2007, 6:154-162.
9. Taylor R.C., Acquaah-Mensah G., Singhal M., Malhotra D., Biswal S. Network inference algorithms elucidate Nrf2 regulation of mouse lung oxidative stress. PLoS Comput. Biol. 2008, 4:e1000166.
10. Alam J., Stewart D., Touchard C., Boinapally S., Choi A.M., Cook J.L. Nrf2, a Cap'n'Collar transcription factor, regulates induction of the heme oxygenase-1 gene. J. Biol. Chem. 1999, 274:26071-26078.
11. Aminzadeh M.A., Nicholas S.B., Norris K.C., Vaziri N.D. Role of impaired Nrf2 activation in the pathogenesis of oxidative stress and inflammation in chronic tubulo-interstitial nephropathy. Nephrol. Dial. Transplant. 2013, 28:2038-2045.
12. Ungvari Z., Bagi Z., Feher A., Recchia F.A., Sonntag W.E., Pearson K., de Cabo R., Csiszar A. Resveratrol confers endothelial protection via activation of the antioxidant transcription factor Nrf2. Am. J. Physiol. Heart Circ. Physiol. 2010, 299:H18-24.
13. Gomez-Guzman M., Jimenez R., Sanchez M., Zarzuelo M.J., Galindo P., Quintela A.M., Lopez-Sepulveda R., Romero M., Tamargo J., Vargas F., Perez-Vizcaino F., Duarte J. Epicatechin lowers blood pressure, restores endothelial function, and decreases oxidative stress and endothelin-1 and NADPH oxidase activity in DOCA-salt hypertension. Free Radic. Biol. Med. 2012, 52:70-79.
14. Dinkova-Kostova A.T., Liby K.T., Stephenson K.K., Holtzclaw W.D., Gao X., Suh N., Williams C., Risingsong R., Honda T., Gribble G.W., Sporn M.B., Talalay P. Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress. Proc. Nat. Acad. Sci. U.S.A. 2005, 102:4584-4589.
15. Liby K.T., Yore M.M., Sporn M.B. Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer. Nat. Rev. Cancer 2007, 7:357-369.
16. Liby K.T., Sporn M.B. Synthetic oleanane triterpenoids: multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease. Pharmacol. Rev. 2012, 64:972-1003.
17. Vaziri N.D., Bai Y., Ni Z., Quiroz Y., Pandian R., Rodriguez-Iturbe B. Intra-renal angiotensin II/AT1 receptor, oxidative stress, inflammation, and progressive injury in renal mass reduction. J. Pharmacol. Exp. Ther. 2007, 323:85-93.
18. Kamanna V.S., Ganji S.H., Shelkovnikov S., Norris K., Vaziri N.D. Iron sucrose promotes endothelial injury and dysfunction and monocyte adhesion/infiltration. Am. J. Nephrol. 2012, 35:114-119.
19. Kim H.J., Sato T., Rodriguez-Iturbe B., Vaziri N.D. Role of intrarenal angiotensin system activation, oxidative stress, inflammation, and impaired nuclear factor-erythroid-2-related factor 2 activity in the progression of focal glomerulosclerosis. J. Pharmacol. Exp. Ther. 2011, 337:583-590.
20. Shelkovnikov S., Summers S.M., Elahimehr R., Adams G., Purdy R.E., Vaziri N.D. Effect of exercise training on aortic tone in chronic renal insufficiency. Am. J. Hypertens. 2008, 21:564-569.
21. Yamamizu K., Shinozaki K., Ayajiki K., Gemba M., Okamura T. Oral administration of both tetrahydrobiopterin and l-arginine prevents endothelial dysfunction in rats with chronic renal failure. J. Cardiovasc. Pharmacol. 2007, 49:131-139.
22. Kurowska E.M. Nitric oxide therapies in vascular diseases. Curr. Pharm. Des. 2002, 8:155-166.
23. Zhang H., Schmeisser A., Garlichs C.D., Plotze K., Damme U., Mugge A., Daniel W.G. Angiotensin II-induced superoxide anion generation in human vascular endothelial cells: role of membrane-bound NADH-/NADPH-oxidases. Cardiovasc. Res. 1999, 44:215-222.
24. Uderhardt S., Kronke G. 12/15-lipoxygenase during the regulation of inflammation, immunity, and self-tolerance. J. Mol. Med. (Berl) 2012, 90:1247-1256.
25. Afonyushkin T., Oskolkova O.V., Philippova M., Resink T.J., Erne P., Binder B.R., Bochkov V.N. Oxidized phospholipids regulate expression of ATF4 and VEGF in endothelial cells via NRF2-dependent mechanism: novel point of convergence between electrophilic and unfolded protein stress pathways. Arterioscler. Thromb. Vasc. Biol. 2010, 30:1007-1013.
26. Meyer N., Akdis C.A. Vascular endothelial growth factor as a key inducer of angiogenesis in the asthmatic airways. Curr. Allergy Asthma Rep. 2013, 13:1-9.
27. Juncos J.P., Grande J.P., Kang L., Ackerman A.W., Croatt A.J., Katusic Z.S., Nath K.A. MCP-1 contributes to arteriovenous fistula failure. J. Am. Soc. Nephrol. 2011, 22:43-48.